Cara Therapeutics, Inc.

CARA


Canadian symbol: CARA
US symbol: CARA

Currency in USD

Valuation Measures

Market Cap (intraday) 5825.02M
Enterprise Value 3708.91M
Trailing P/E N/A
Forward P/E 1-7.17
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)34.96
Price/Book (mrq)5.13
Enterprise Value/Revenue 330.04
Enterprise Value/EBITDA 6-5.99

Trading Information

Stock Price History

Beta (5Y Monthly) 1.94
52-Week Change 3-30.65%
S&P500 52-Week Change 35.66%
52 Week High 327.55
52 Week Low 38.88
50-Day Moving Average 316.51
200-Day Moving Average 315.39

Share Statistics

Avg Vol (3 month) 3545.68k
Avg Vol (10 day) 3363.1k
Shares Outstanding 546.8M
Float 42.52M
% Held by Insiders 12.51%
% Held by Institutions 168.98%
Shares Short (Jun. 14, 2020) 43.58M
Short Ratio (Jun. 14, 2020) 46.95
Short % of Float (Jun. 14, 2020) 48.75%
Short % of Shares Outstanding (Jun. 14, 2020) 47.66%
Shares Short (prior month May 14, 2020) 43.74M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:2
Last Split Date 3Jan. 15, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-502.38%

Management Effectiveness

Return on Assets (ttm)-40.40%
Return on Equity (ttm)-82.43%

Income Statement

Revenue (ttm)23.6M
Revenue Per Share (ttm)0.53
Quarterly Revenue Growth (yoy)84.70%
Gross Profit (ttm)-93.93M
EBITDA -118.35M
Net Income Avi to Common (ttm)-113.33M
Diluted EPS (ttm)-2.55
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)120.2M
Total Cash Per Share (mrq)2.57
Total Debt (mrq)4.09M
Total Debt/Equity (mrq)2.55
Current Ratio (mrq)4.07
Book Value Per Share (mrq)3.43

Cash Flow Statement

Operating Cash Flow (ttm)-120M
Levered Free Cash Flow (ttm)-72.77M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CARA
Cara Therapeutics
3 weeks ago
CARA
Cara Therapeutics
3 weeks ago
CARA
Cara Therapeutics
1 month ago
CARA
Cara Therapeutics
1 month ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
5 months ago
CARA
Cara Therapeutics
5 months ago
CARA
Cara Therapeutics
6 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
12 months ago
CARA
Cara Therapeutics
12 months ago
CARA
Cara Therapeutics
12 months ago
CARA
Cara Therapeutics
12 months ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago

Currency in USD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts7788
Avg. Estimate-0.67-0.69-2.61-2.46
Low Estimate-0.8-0.77-2.99-3.3
High Estimate-0.48-0.49-2.03-1.52
Year Ago EPS-0.58-0.74-2.49-2.61
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts7788
Avg. Estimate5.06M4.77M21.87M34.13M
Low Estimate4M4M20M19.1M
High Estimate6M5.6M23.9M60M
Year Ago Sales5.21M5.79M19.89M21.87M
Sales Growth (year/est)-2.80%-17.50%10.00%56.10%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.61-0.58-0.66-0.62
EPS Actual-0.58-0.74-0.61-0.62
Difference0.03-0.160.050
Surprise %4.90%-27.60%7.60%0.00%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate-0.67-0.69-2.61-2.46
7 Days Ago-0.67-0.69-2.61-2.46
30 Days Ago-0.67-0.69-2.61-2.46
60 Days Ago-0.64-0.69-2.6-2.24
90 Days Ago-0.63-0.69-2.61-2.26
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesCARAIndustrySector(s)S&P 500
Current Qtr.-15.50%N/AN/AN/A
Next Qtr.6.80%N/AN/AN/A
Current Year-4.80%N/AN/AN/A
Next Year5.70%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
2.51%% of Shares Held by All Insider
68.98%% of Shares Held by Institutions
70.76%% of Float Held by Institutions
209Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Price (T.Rowe) Associates Inc3,865,390Mar. 30, 20208.26%51,061,801
Blackrock Inc.3,498,244Mar. 30, 20207.48%46,211,803
RHO Capital Partners Inc3,193,057Mar. 30, 20206.82%42,180,282
Farallon Capital Management LLC2,300,000Mar. 30, 20204.91%30,383,000
Vanguard Group, Inc. (The)2,276,697Mar. 30, 20204.87%30,075,167
Carmignac Gestion1,787,062Mar. 30, 20203.82%23,607,089
First Manhattan Company1,442,421Mar. 30, 20203.08%19,054,381
Chescapmanager LLC1,305,409Mar. 30, 20202.79%17,244,452
State Street Corporation1,021,070Mar. 30, 20202.18%13,488,334
Bank of America Corporation904,297Mar. 30, 20201.93%11,945,763

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Vanguard Total Stock Market Index Fund1,260,328Mar. 30, 20202.69%16,648,932
ETF Managers Tr-EFTMG Alternative Harvest ETF879,858Mar. 30, 20201.88%11,622,924
iShares Russell 2000 ETF868,191Apr. 29, 20201.86%12,866,590
Price (T.Rowe) Health Sciences Fund844,398Mar. 30, 20201.80%11,154,497
Price (T.Rowe) New Horizons Fund797,880Mar. 30, 20201.71%10,539,994
Price (T.Rowe) Small-Cap Value Fund672,993Mar. 30, 20201.44%8,890,237
Vanguard Extended Market Index Fund616,303Mar. 30, 20201.32%8,141,362
iShares NASDAQ Biotechnology ETF437,991Apr. 29, 20200.94%6,491,026
Price (T.Rowe) Small Cap Stock Fund418,107Mar. 30, 20200.89%5,523,193
iShares Russell 2000 Growth ETF301,577Apr. 29, 20200.64%4,469,371
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Cara Therapeutics, Inc.


Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

STAMFORD, Conn., June 30, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced the appointment of Susan Shiff, Ph.D., M.B.A., to its Boar... Read More...
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVAâ„¢ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVAâ„¢ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

- Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of  >4-point improvement responder analysis -- Full trial enrollment expected in fourth quarter of 2020 - STAMFORD, Conn., June 17, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical... Read More...
Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

STAMFORD, Conn., May 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...
Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

STAMFORD, Conn., May 07, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...
Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

STAMFORD, Conn., May 04, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast o... Read More...
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVAâ„¢ injection in haemodialysis patients with Pruritus

VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVAâ„¢ injection in haemodialysis patients with Pruritus

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching intens... Read More...
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) -Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching inten... Read More...
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

STAMFORD, Conn., April 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Ex... Read More...
Cara Therapeutics Reports Clinical Updates

Cara Therapeutics Reports Clinical Updates

- On track to report topline data for KALM-2 Phase 3 global trial of  KORSUVA™ Injection in second quarter –                   - On track to complete interim statistical analysis for ongoing Phase 2 trial of Oral KORSUVA in atopic dermatitis in second quarter - - Timeline to submit KORSUVA Injection New Drug Application to FDA in second h... Read More...
Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

STAMFORD, Conn., Feb. 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced financial results and operational highlights for the fourt... Read More...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

STAMFORD, Conn., Feb. 20, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast ... Read More...
Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 38th Annual J.P. Morgan Healthcare ... Read More...
Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

STAMFORD, Conn., Dec. 06, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved t... Read More...
Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 31st Annual Piper Jaffray Healthcar... Read More...
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) –– Oral KORSUVA™ well-tolerated after 12 weeks of treatment –– Conference call today at 8:30 a.m. ET –STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics,... Read More...
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVAâ„¢ Injection) KALMâ„¢-1 Phase 3 Trial Results in the New England Journal of Medicine

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVAâ„¢ Injection) KALMâ„¢-1 Phase 3 Trial Results in the New England Journal of Medicine

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="- Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and secondary endpoints -" data-... Read More...
Cara Therapeutics Reports Third Quarter 2019 Financial Results

Cara Therapeutics Reports Third Quarter 2019 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Nov. 05, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results and operational ... Read More...
Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

STAMFORD, Conn., Oct. 29, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Tues... Read More...
Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

- Patient enrollment increased approximately 20% to maintain >90% statistical power - - Full trial enrollment expected in fourth quarter of 2019 -STAMFORD, Conn., Oct. 14, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treat... Read More...
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

STAMFORD, Conn., Sept. 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 2019 Cantor Fitzgerald Global... Read More...
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

STAMFORD, Conn., Aug. 21, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has entered into a non-exclusive commerci... Read More...
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

Deal Showcases the Potential of Peptelligence® as the "Gold Standard" Technology for Developing Oral Formulations of Peptide-Based DrugsOral KORSUVA™ is Currently the Subject of Three Separate Phase 2 Clinical Trials for Differing Indications of PruritisBOONTON, N.J., Aug. 21, 2019 -- Enteris BioPharma, Inc., a biotechnology company devel... Read More...
Cara Therapeutics Reports Second Quarter 2019 Financial Results

Cara Therapeutics Reports Second Quarter 2019 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Aug. 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results and oper... Read More...
Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

STAMFORD, Conn., July 31, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Wedn... Read More...
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

STAMFORD, Conn., July 29, 2019 -- Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering of 6,325,000... Read More...
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the pricing of its underwritten public offering... Read More...
Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

- Study now fully enrolled; topline data expected in 4Q 2019 -STAMFORD, Conn., July 22, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced t... Read More...
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVAâ„¢ for Pruritus in Patients with Atopic Dermatitis

Oral KORSUVA is now the subject of three separate, ongoing Phase 2 clinical trialsBOONTON, N.J., July 11, 2019 -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (CARA) on the successful initiation of its Phase 2 clinic... Read More...
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

STAMFORD, Conn., July 09, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefal... Read More...
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)

STAMFORD, Conn., June 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefal... Read More...
Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) –- Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itchi... Read More...
Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the Bank of America Merrill Lynch 2019 H... Read More...
Cara Therapeutics Reports First Quarter 2019 Financial Results

Cara Therapeutics Reports First Quarter 2019 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., May 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting peripheral kappa opioid receptors, today announced financial... Read More...
Coming Soon.

Delayed data (1h)


Share this page